在低滴度O型通用供血时代,血型特异性全血仍有用武之地
本文为综述,梳理血型特异性全血(TSWB)与低滴度O型通用供血全血(LTOWB)的使用历史与现状:美国军队血液项目1965年起使用TSWB以扩大供者池,美国血库协会(AABB)1958年至2018年指南仅允许TSWB;2015年美军在部署环境重新引入LTOWB,2018年获AABB认可并在全球军民中逐步推广。作者提出保留TSWB的4条理由:ABO不相容血浆免疫学并发症风险尚未明确、大量输注LTOWB的风险(历史建议输注大量LTOWB后2至3周内不输注血型特异性血)、「低滴度」最佳定义不确定、扩大供者池。作者认为,在患者血型已确认且有血液学实验室的机构应优先选择TSWB,LTOWB仅用于血型未知者。
要点
- 作者认为:在患者血型已确认、具备血液学实验室的机构,应优先使用血型特异性全血(TSWB),LTOWB保留给血型未知的患者。
- 院前环境下LTOWB是唯一实用的解决方案;这是原文明确给出的场景限定。
- 原文引用的历史建议(基于临床经验):大量输注LTOWB后2至3周内不输注血型特异性血。
- 保留TSWB的4条理由:ABO不相容血浆免疫学并发症风险尚未明确、大量LTOWB输注风险、低滴度最佳定义不确定、扩大供者池。
- 目前正在进行的多项大型随机对照试验比较LTOWB与成分输血,但均未回答LTOWB与TSWB孰优的问题。
适用人群与场景
- 严重创伤出血患者,涉及院前与院内输血场景。
- 院前环境下,血型未知时使用LTOWB是唯一实用的解决方案。
- 院内具备血液学实验室且患者血型已确认时,作者认为应优先选择TSWB。
处置流程与药物剂量
- 院前:LTOWB是唯一实用的解决方案。
- 院内:患者血型已确认且有血液学实验室时,作者认为应优先选择TSWB;LTOWB保留给血型未知的患者。
- 原文引用的历史建议(基于临床经验):大量输注LTOWB后2至3周内不输注血型特异性血。
研究设计与关键结果
- 美国军队血液项目1965年开始使用TSWB以扩大供者池;AABB自1958年首版指南至2018年仅允许TSWB。
- 为缩短输血时间,美军2015年在部署环境重新引入LTOWB,2018年获AABB认可,并在全球军民中逐步推广。
- 保留TSWB的4条理由:(1)ABO不相容血浆(即使抗A、抗B滴度低)的免疫学并发症风险尚未明确;(2)大量输注LTOWB的风险,包括历史建议大量输注LTOWB后2至3周内不输注血型特异性血;(3)「低滴度」的最佳定义不确定;(4)允许血型特异性输血可扩大潜在供者池。
- 目前多项大型随机对照试验比较LTOWB与成分输血,但均未涉及LTOWB与TSWB的比较。
- 作者认为有足够数据提示应避免对非O型受血者输注LTOWB的额外风险,尽早使用TSWB;结合高需求时维持充足血液制品供应的优势,提示在民用与军用血液供应系统中保留TSWB是可取的。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为:在患者血型已确认、具备血液学实验室的机构应优先使用TSWB,LTOWB保留给血型未知的患者。
- 作者认为:应避免对非O型受血者输注LTOWB的额外风险,尽早使用TSWB。
- 作者认为:在民用与军用血液供应系统中保留TSWB是可取的。
- 院前环境下LTOWB仍是唯一实用的解决方案,不因上述建议而改变。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Whole blood can be ABO-type specific (type-specific whole blood (TSWB)) or low-titer O universal donor (low-titer O whole blood (LTOWB)). Having previously used LTOWB, the US Armed Forces Blood Program began using TSWB in 1965 as a method of increasing the donor pool. In contrast to military practice, the Association for the Advancement of Blood and Biotherapies formerly the American association of blood banks (AABB), from its first guidelines in 1958 until 2018, permitted only TSWB. Attempting to reduce time to transfusion, the US military reintroduced LTOWB in the deployed environment in 2015; this practice was endorsed by the AABB in 2018 and is progressively being implemented by military and civilian providers worldwide. Low-titer O whole blood is the only practical solution prehospital. However, there are several reasons to retain the option of TSWB in hospitals with a laboratory. These include (1) as-yet ill-defined risks of immunological complications from ABO-incompatible plasma (even when this has low titers of anti-A and -B), (2) risks of high volumes of LTOWB including published historical advice (based on clinical experience) not to transfuse type-specific blood for 2 to 3 weeks following a substantial LTOWB transfusion, (3) uncertainty as to the optimal definition of "low titer," and (4) expanding the potential donor pool by allowing type-specific transfusion. Several large randomized controlled trials currently underway are comparing LTOWB with component therapy, but none address the question of LTOWB versus TSWB. There are sufficient data to suggest that the additional risks of transfusing LTOWB to non-group O recipients should be avoided by using TSWB as soon as possible. Combined with the advantage of maintaining an adequate supply of blood products in times of high demand, this suggests that retaining TSWB within the civilian and military blood supply system is desirable. TSWB should be preferred when patient blood group is confirmed in facilities with a hematology laboratory, with LTOWB reserved for patients whose blood group is unknown.
参考来源
- Milford EM, Gurney JM, Beckett A, et al. Type-specific whole blood still has a role in the era of low-titer O universal donor transfusion for severe trauma hemorrhage. J Trauma Acute Care Surg. 2024. PMID: 38764142. doi:10.1097/TA.0000000000004369
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。